Lee Chul Kyu, Shin Jang Sik, Kim Byung Su, Cho Il Hwan, Kim Young Shik, Lee Eun Bang
Central Research Institute, Shin Poong Pharm. Co. Ltd., Ansan, Korea.
Arch Pharm Res. 2007 Apr;30(4):475-80. doi: 10.1007/BF02980222.
A novel proteinase fraction, SPP-501, was purified from the earthworm, Eisenia andrei, and its antithrombotic effects compared with those of urokinase and t-PA (tissue type-plasminogen activator) in a thrombosis model, induced by the insertion of a stainless wire coil into the inferior vena cava. SPP-501, urokinase and t-PA were administrated once a day for 14 days. On the oral administration of SPP-501, as well as urokinase and t-PA, the thrombus weight was dramatically decreased. The euglobulin lysis time (ELT) was also shortened by SPP-501, but urokinase and t-PA failed to dissolve the euglobulin clot. Conversely, urokinase and t-PA produced detectable fibrinogen/fibrin degradation products (FDP), but SPP-501 did not. Thrombin induced platelet aggregation was desensitized in the SPP-501 treatment groups. With a high dose of SPP-501 (45 mg/kg), the APTT (activated partial thromboplastin time) was prolonged. These results suggest that SPP-501 shows both antithrombotic and fibrinolytic activities when orally administered.
从安德爱胜蚓（Eisenia andrei）中纯化出一种新型蛋白酶组分SPP - 501，并在将不锈钢丝圈插入下腔静脉诱导形成的血栓模型中，将其抗血栓作用与尿激酶和组织型纤溶酶原激活剂（t - PA）进行比较。SPP - 501、尿激酶和t - PA每天给药一次，持续14天。口服SPP - 501以及尿激酶和t - PA后，血栓重量显著降低。SPP - 501也缩短了优球蛋白溶解时间（ELT），但尿激酶和t - PA未能溶解优球蛋白凝块。相反，尿激酶和t - PA产生了可检测到的纤维蛋白原/纤维蛋白降解产物（FDP），但SPP - 501没有。在SPP - 501治疗组中，凝血酶诱导的血小板聚集作用减弱。高剂量（45 mg/kg）的SPP - 501可延长活化部分凝血活酶时间（APTT）。这些结果表明，口服SPP - 501时具有抗血栓和纤溶活性。
